EP0198003A1 - Compositions calmantes de la toux - Google Patents

Compositions calmantes de la toux

Info

Publication number
EP0198003A1
EP0198003A1 EP85905100A EP85905100A EP0198003A1 EP 0198003 A1 EP0198003 A1 EP 0198003A1 EP 85905100 A EP85905100 A EP 85905100A EP 85905100 A EP85905100 A EP 85905100A EP 0198003 A1 EP0198003 A1 EP 0198003A1
Authority
EP
European Patent Office
Prior art keywords
carrier
process according
compositions
fat
hog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85905100A
Other languages
German (de)
English (en)
Inventor
Gáspár LEOPOLD
Attila Sziklai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEKE MGTSZ
Original Assignee
BEKE MGTSZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEKE MGTSZ filed Critical BEKE MGTSZ
Publication of EP0198003A1 publication Critical patent/EP0198003A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts

Definitions

  • the present invention relates to physiologically calmative and sedative cough-relieving compositions and a method for relieving cough by the aid of the said compositions.
  • Codein morphine monomethyl ether
  • other galenic formulations e.g. anisated expectorant liquid, elixir comprising eucalyptus oil or thimal
  • Hog-fat is used for the easing of cough in the traditional popular therapy.
  • the great disadvantage of the synthetic medicaments is that they comprise smaller or higher amount of exciting alkaloids, therefore certain compositions are considered as doping (stimulating) agents.
  • the alkaloids can also have an undesired side-effect to the heart.
  • the drawback of the galenic formulations is that their effect is relatively weak. According to French Patent Specification
  • compositions according to the present invention comprise hog-fat, eucalyptus oil and optionally mustard in a weight ratio of 700 to 1200 : : 2.5 to 50 : 70 to 160 as active ingredients.
  • composition is not sterilized, it should also comprise an antioxidant.
  • the weight ratio of hog-fat to the antioxydant should be 700 to 1200 : : 0.1 to 5.
  • compositions according to the invention are assured by hog-fat, eucalyptus oil and mustard, latter being optionally present.
  • Mustard is not an essential element of the compositions, however, its addition enhances the activity of the compositions.
  • the active ingredient of the hog-fat is mainly prostaglandine but also the volatile fatty acids ( triglycerides) have a favourable effect on the inner cilia of the bronchi.
  • the active ingredient of cough-relieving and expectorant effect of mustard is mustard oil.
  • the cough-relieving effect of eucalyptus oil is known, but in our case it is also useful for the perfuming of the composition.
  • the effect of the compositions of the invention is different from the additive effect of hog-fat, eucalyptus oil and mustard which components all have a very low effect per se, as it is widely known. These components synergistically enhance each-others activity.
  • compositions exerts their effect partly transdermally, partly by the route of evaporation inhalation.
  • the temperature needed for the latter process is assured by the constant temperature of the human body.
  • the composition can be sterilized, but the sufficient chemical and microbiological stability can also be assured by addition of an antioxidant.
  • an antioxidant preferably butyl hydroxytoluene, commonly used for protecting hog-fat from growing rancid, can be used.
  • the active agents of the invention can be applied onto the skin by any means that produces contact of the active agent with the agent's site of action. They can be administered by any conventional means available for use. They can be applied alone, but are generally applied with a pharmaceutical carrier.
  • composition When the composition is formulated as a plaster the active ingredients are preferably absorbed by a suitable carrier, optionally covered by a removable protective layer and the carrier is preferably supplied with means suitable for fixing the carrier onto the skin.
  • suitable carrier gauze bandage purified cotton, absorbent gauze, terry cloth or any other hydrophobic, soft, non-irritating material can be mentioned.
  • the carrier is preferably impregnated on the back side by e.g. a polymer such as polyvinyl chloride, or such a carrier is used of which the back side is of close texture.
  • a suitable insulating material e.g. aluminium or polymer foil onto the back side of the carrier.
  • the mixture of the active ingredients can be applied onto the chest of the patient confined to bed per se, or absorbed by a suitable carrier, the carrier is preferably fixed onto the skin of the patient.
  • the fixing can be carried out by sticking the carrier saturated by the active ingredients on its two or four edges onto the skin by the aid of adhesive plaster stripes, but the carrier can also be put onto a piece of an adhesive plaster being bigger in size than the carrier itself and the parts of the plaster overlaping the carrier fasten the carrier to the akin.
  • the adhesive tape can be of the surgical type with an adhesive being neutral from the point of view of skin allergy.
  • the tape can be a rubber based one or can have an acrylate coating attached.
  • the adhesive tape can be woven or nonwoven fabric.
  • That side of the carrier saturated with the active ingredients which will contact the skin is preferably covered by a protective layer which can be removed before use.
  • a protective layer polyvinyl chloride, polyethylene or aluminium foil can preferably be used.
  • the active ingredients can also be incorporated into creams, dressings, glycerogelatins, pastes and ointments.
  • vaseline or any other carrier commonly used in such types of pharmaceutical formulations can be employed as carrier.
  • the plaster according to the invention suitable for external application contains from about 1 g to 100 g of active ingredients per unit.
  • the active ingredients will ordinarily be present in an amount of about 5 to 100 % by weight based on the total weight of the compositions.
  • the composition according to Figure 1 is prepared by saturating the 1 terry cloth piece with the mixture of the active ingredients in an amount of 250 to 2500 g/m 2 , sticking the 2 polyvinyl chloride or other foil to one of ita aides, placing this side onto the 3 adhesive plaster and covering the other side which will be in contact with the skin with the 4 polyvinyl or polyethylene foil which can be removed before use.
  • the preferred form of the preparation according to the invention is a square or rectangle with 10 to 20 cm sides.
  • the preparation according to the invention has no side-effect, it is not toxic. It exhibits its effect already within 10 to 15 minutes and this effect is exerted throughout 6 to 8 hours. Thereafter the treatment can be repeated without any harmful consequence. Its application is simple, it can be used disregard to the age of the patient and the section of the day.
  • the invention is illustrated by the following, non-limiting examples.
  • Example 1 hog-fat 1000 g eucalyptus oil 3 g butyl hydroxytoluene 0.1 g
  • terry cloth (10x20 cm) is aaturated with the mixture. That side of the terry cloth which will not contact the skin is of close structure in order to prevent the evaporation of the volatile oil and the penetration of hog-fat.
  • the carrier saturated like this is applied onto a 13x13 cm piece of an adhesive plaster and that side of the terry cloth which will contact the skin is covered by a polyvinyl chloride foil,
  • Example 2 hog-fat 1200 g eucalyptus oil 43 g butyl hydroxytoluene 3 g mustard 90 g
  • the above components are mixed and a
  • 20x20 cm piece of gauze is aaturated with the mixture, One side of the gauze is impregnated with polyvinyl chloride and it is fixed onto the cheat of the patient by the aid of two atripes of an adhesive plaster being on the opposite sides of the carrier.
  • the above components are mixed, thereafter the mixture is sterilized and cooled.
  • a hydrophobic textile (10x15 cm) is saturated with this mixture and a polyvinyl chloride foil of the same size is sticked onto that aide of the material which will not contact the akin.
  • the carrier is applied onto a 12 x 17 cm piece of an adhesive plaster, thereafter that part of the carrier, which will contact the akin is covered with a polyethylene foil.
  • Example 5 Ointment hog-fat 700 g eucalyptus oil 5 g mustard 70 g butyl hydroxytoluene 5 g vaseline 1000 g
  • the ingredients are thoroughly mixed.
  • the effect of the composition according to the invention is verified by the following tests: The composition according to Example 2 was applied.
  • the composition was applied onto the cheat of 17 patients suffering from asthma or bronchitis. The cough completely ceased in the case of 8 patients, it was relieved in great extent in 5 cases and in less extent in 4 cases. The composition was applied for night. No disadvantageous or harmful side-effect could be observed.
  • the composition was applied onto the chest of 4 children suffering from double form of chronic bronchitis. The cough was significantly relieved even due to only one treatment and the stethoscopic diagnosis improved as well in all the four cases, c) The composition was applied onto the chest of 10 patients. The results are summarized in Table 1. Table 1
  • composition was applied onto the chest of 10 1 to 4 years old and 10, 5 to 14 years old patients suffering from obstructive bronchitis, asthma bronchiale or bronchopneumonia.
  • the composition was applied at night, before going to bed for the younger children, while it was used at night and day too, for the elder children, in both cases as a supplement of the basic medicines.
  • the younger children (1 to 4 years old) became aubatantially tranquil, they could better sleep, while they auffered from air-thrist before the application of the composition.
  • the effect of the composition decreased after about 2 hours.
  • a carrier was saturated with mustard and this waa applied to the chest of the same 6 patients. No effect could be observed in any one of the cases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Des compositions pharmaceutiques synergétiques ont un effet calmant sur la toux, et un procédé permet de calmer la toux à l'aide de ces compositions. Les ingrédients actifs de la composition sont la graisse de porc, l'huile d'eucalyptus et facultativement de la moutarde.
EP85905100A 1984-10-12 1985-10-11 Compositions calmantes de la toux Withdrawn EP0198003A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU304882 1984-10-12
HU823048A HU187414B (en) 1984-10-12 1984-10-12 Process for producing cough-preparation of physiologically relieving and sedative effect, fixable on skin

Publications (1)

Publication Number Publication Date
EP0198003A1 true EP0198003A1 (fr) 1986-10-22

Family

ID=10962279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85905100A Withdrawn EP0198003A1 (fr) 1984-10-12 1985-10-11 Compositions calmantes de la toux

Country Status (5)

Country Link
EP (1) EP0198003A1 (fr)
DD (1) DD243642A5 (fr)
DK (1) DK277486A (fr)
HU (1) HU187414B (fr)
WO (1) WO1986002270A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433191A1 (de) * 1994-09-17 1996-03-21 Lohmann Therapie Syst Lts Selbstklebendes Pflaster zur Abgabe von Wirkstoff an die Umgebung eines Trägers
AU2000250055A1 (en) * 2000-04-13 2001-10-30 Lectec Corporation Therapeutic patch containing a liquid or gel organic compound as a carrier
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
CN104971322A (zh) * 2015-06-11 2015-10-14 钟兴欢 一种黄皮清咽润喉片

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB190719133A (en) * 1907-08-26 1908-05-07 William Bryant An Improved Ointment
AT261811B (de) * 1963-11-18 1968-05-10 Sophie Lintner Verfahren zur Herstellung einer homogenen Salbe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8602270A1 *

Also Published As

Publication number Publication date
DD243642A5 (de) 1987-03-11
WO1986002270A1 (fr) 1986-04-24
DK277486D0 (da) 1986-06-12
HU187414B (en) 1986-01-28
DK277486A (da) 1986-07-28

Similar Documents

Publication Publication Date Title
US5601838A (en) Method for treating pain associated with herpes-zoster and post-herpetic neuralgia
US5976547A (en) Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
AU2001245449B2 (en) Intradermal-penetration agents for topical local anesthetic administration
KR0143916B1 (ko) 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법
US20060029654A1 (en) Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain
US5612382A (en) Composition for percutaneous absorption of pharmaceutically active ingredients
AU2001245449A1 (en) Intradermal-penetration agents for topical local anesthetic administration
ATE162399T1 (de) Terfanadin metaboliten und deren optisch reine isomere zur behandlung von allergischen krankheiten
JP4596751B2 (ja) 消炎鎮痛貼付剤
EP0198003A1 (fr) Compositions calmantes de la toux
JP4041162B2 (ja) ルビジウムイオンを用いる製剤
TW305761B (fr)
EP0002003B1 (fr) Compositions médicales et cosmétiques contenant un dérivé thixotropique d'aluminium; leur procédé d'obtention
EP0260645A1 (fr) Système thérapeutique pour l'application locale de composés pharmaceutiques
JPS60163811A (ja) プロプラノロ−ル含有外用貼付剤
RU2177314C2 (ru) Состав с антисептическими, репаративными и болеутоляющими свойствами
Price How essential oils enter the body
US3098790A (en) Admixture of aluminum metal powder and powdered vegetable gum for treatment of open wounds
JPH10265405A (ja) インスリン含有の皮膚外用製剤
Ohlsen et al. New anaesthetic formulation for epicutaneous application tested for cutting split skin grafts
JP2002080386A (ja) 貼着用テーピング材
JP3036689U (ja) 蓐瘡等の治療用貼付材
JP3612731B2 (ja) 消炎鎮痛外用剤
CA1339073C (fr) Penetration a l'aide d'un systeme binaire de composes perturbant l'enveloppe cellulaire et d'alcools inferieurs
Stenström et al. Leprosy wound healing with ordinary adhesive tape: a preliminary report

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL

17P Request for examination filed

Effective date: 19861002

17Q First examination report despatched

Effective date: 19890120

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900221

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEOPOLD, GASPAR

Inventor name: SZIKLAI, ATTILA